Iconlab Inc. v. Valeant Pharm. Int'l, Inc. (In re Malyugin)
Iconlab Inc. v. Valeant Pharm. Int'l, Inc. (In re Malyugin)
Opinion of the Court
Dr. Boris Malyugin, a Russian national, seeks to quash a third-party subpoena served on him on April 15, 2018 noticing a deposition and the production of documents for April 17, 2018. Mem. in Supp. of Emergency Mot. to Stay and Quash Third-Party Subpoena ("Mot. to Quash")
*52, 8, ECF No. 1-1. Because the subpoena was served two days prior to the deposition, and compliance will require Dr. Malyugin to travel more than 100 miles from where he resides, is employed, or regularly transacts business in person, the motion to quash is granted. See Fed. R. Civ. P. 45(d)(3)(A)(i)-(ii). This Order is issued without prejudice for the parties seeking the testimony and evidence to re-serve Dr. Malyugin with a subpoena in compliance with Rule 45.
In November 2016, Dr. Malyugin executed a declaration in the ongoing matter of Iconlab Inc. et al. v. Valeant Pharms. Int'l, Inc. et al. , 8:16-cv-01321, in the United States District Court for the Central District of California. Defs.' Opp. to Mot. to Quash ("Defs.' Opp") Ex. 5, ECF No. 2-6. The Second Amended Complaint, the operative Complaint, identifies Dr. Malyugin by name a multitude of times and seems to incorporate the information contained in Dr. Malyugin's declaration. See id. Ex. 4, ECF No. 2-5. Because of this, several defendants (the "Defendants") in the underlying litigation sought, starting on March 22, 2018, to depose Dr. Malyugin and sent him and the plaintiffs in the underlying litigation a series of communications about his deposition. Defs.' Opp. 6-7. Dr. Malyugin did not respond to these communications. Id. Once the Defendants learned that Dr. Malyugin was scheduled to be in the United States-more specifically, in the District of Columbia-for the annual meeting of the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrators (to be held April 13, 2018 to April 17, 2018), the Defendants executed and served Dr. Malyugin with a subpoena noticing his deposition for April 17, 2018. Defs.' Opp. 7-8; Mot. to Quash 1-2.
Rule 45(d)(3)(A) requires a court to "quash or modify a subpoena that (i) fails to allow a reasonable time to comply; (ii) requires a person who is neither a party nor a party's officer to travel more than 100 miles from where that person resides, is employed, or regularly transacts business in person [with one exception not relevant here]; (iii) requires disclosure of privileged or other protected matter ...; or (iv) subjects a person to undue burden." Subparts (i) and (ii) are relevant here. The subpoena was served on Dr. Malyugin on April 15, 2018, two days prior to the date of compliance. Two days' notice is plainly unreasonable. See, e.g., Judicial Watch, Inc. v. U.S. Dep't of Commerce ,
While Dr. Malyugin is presently in the District of Columbia and therefore would not currently need to "travel more than 100 miles from where that person resides, *6is employed, or regularly transactions business in person [in this case, the Russia Federation]," his stay in the District of Columbia is temporary. See Mot. to Quash 1-2 (the annual meeting for which Dr. Malyugin is in the District of Columbia ends on April 17, 2018). It is apparently uncontested that he lives and works in Russia. See generally Defs.' Opp. In light of Rule 45(d)(3)(A)(i)'s requirement that a subpoena provide a reasonable amount of time to comply, re-noticing the deposition with a reasonable timeframe for compliance may then violate Rule 45(d)(3)(A)(ii)'s geographical constriction.
The Defendants argue that the subpoena can be modified to give Dr. Malyugin a reasonable time to comply, and that the Defendants are amenable to other measures to lessen any burden on Dr. Malyugin's compliance. Defs.' Opp. 13 (noting the Defendants' willingness to conduct the deposition by video conference and the document production by electronic means). While this Circuit has expressed "the importance of the modification alternative" and instructed courts in this District to "carefully examine the circumstances presented to it and, when appropriate, consider the possibility of modifying the subpoena rather than quashing," Northrop Corp. v. McDonnell Douglas Corp. ,
Last, Dr. Malyugin seeks sanctions on the Defendants under Rule 45(d)(1). I do not find that sanctions are warranted. Given the declaration that Dr. Malyugin executed which attested to having personal knowledge of the facts in the declaration and his ability to "competently testify thereto as if called as a witness in this proceeding," and the numerous references to Dr. Malyugin in the Second Amended Complaint, he is clearly a relevant witness in the underlying litigation. See Defs.' Opp. Exs. 4-5; Fed. R. Civ. P. 26(b)(1) ("Parties may obtain discovery regarding any nonprivileged matter that is relevant to any party's claim or defense...."). The Defendants have persistently and in good faith contacted Dr. Malyugin and/or the plaintiffs in the underlying matter to arrange a deposition at a mutually agreeable time and place without court intervention. See, e.g. , Defs.' Opp. Ex. 14, ECF No. 2-15. The Defendants have consistently indicated their willingness to work with Dr. Malyugin to obtain the information they seek, including potentially withdrawing the subpoena altogether if Dr. Malyugin does not intend to submit further evidence or to testify in the underlying litigation.
For the foregoing reasons, it is hereby
ORDERED that Dr. Malyugin's Motion to Quash is GRANTED. It is further
ORDERED that Dr. Malyugin's Motion to Stay is DENIED as moot.
Reference
- Full Case Name
- IN RE Third Party Subpoena to Boris MALYUGIN, M.D. Ph.D. Iconlab Inc. v. Valeant Pharmaceuticals International, Inc.
- Cited By
- 2 cases
- Status
- Published